Patent ID: 7598268
Filing Date: 2009-10-06
Classification: A61K,A61P,C07D

Abstract:
1. A method of treating a cancer patient in need of an inhibitor of a receptor tyrosine kinase, comprising: administering an effective amount of a compound, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a pharmaceutical formulation comprising the compound, the tautomer of the compound, the pharmaceutically acceptable salt of the compound, and/or the pharmaceutically acceptable salt of the tautomer to a patient in need thereof, wherein the receptor tyrosine kinase is vascular endothelial growth factor receptor tyrosine kinase or basic fibroblast growth factor receptor and the receptor tyrosine kinase is inhibited in the patient, after administration and further wherein the compound is 4-amino-5-fluoro-3[5-4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one.